Pricing Log in Create free account

Fate Therapeutics, Inc. (FATE) vs Q32 Bio Inc. (QTTB)

Fate Therapeutics, Inc. and Q32 Bio Inc. are both Biotechnology companies. Fate Therapeutics, Inc. and Q32 Bio Inc. are of similar size ($231.3M and $230.7M). Fate Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Q32 Bio Inc. trades at 2.5×. Fate Therapeutics, Inc. grew revenue faster over the last twelve months: −23.4% against −307.3%. Q32 Bio Inc. has the higher net margin (0.00% vs −1,941.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Q32 Bio Inc. leads on 12 and Fate Therapeutics, Inc. on 2.

Valuation

Metric FATE QTTB Biotechnology median
P/E n/m 2.49 8.50
P/S 33.20 n/m 9.71
P/B 1.40 1.44 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 13.12 (8.25) 9.21
Earnings yield (58.66%) 40.16% (33.15%)
Free cash flow yield (48.92%) (8.43%) (25.50%)

Profitability

Metric FATE QTTB Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (2,058.08%) 0.00% 0.00%
Net margin (1,941.09%) 0.00% 0.00%
Free cash flow margin (1,624.06%) 0.00% 0.00%
Return on equity (60.75%) 72.14% (56.36%)
Return on assets (39.89%) 37.13% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric FATE QTTB Biotechnology median
Revenue growth (TTM) (23.36%) (307.33%) 6.02%
EPS growth (last fiscal year) 29.88% 148.96% 30.26%
Revenue growth, 5-year CAGR (26.71%) 100.32% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FATE QTTB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.85 20.30 4.72
Net debt to EBITDA 1.47 (2.21) 0.96

Dividend

Metric FATE QTTB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric FATE QTTB Biotechnology median
Market cap 230.65m 231.31m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack